Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines
International Journal of Molecular Sciences · 25.10.2024 · 25 (21) · 11461
DOI: 10.3390/ijms252111461 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.10.2024. Verfasst von Roberta Di Benedetto und 8 weiteren Autor:innen. Beteiligte Einrichtung: GSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, Antigens, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals SA.
Abstract (Originalsprache)
Alum is the most used vaccine adjuvant, due to its safety, low cost and adjuvanticity to various antigens. However, the mechanism of action of alum is complex and not yet fully understood, and the immune responses elicited can be weak and antigen-dependent. While several antigens rapidly desorb from alum upon exposure to serum, phosphorylated proteins remain tightly bound through a ligand-exchange reaction with surface hydroxyls on alum. Here, bacterial proteins and glycoconjugates have been modified with phosphoserines, aiming at enhancing the binding to alum and prolonging their bioavailability. Tetanus toxoid protein and Salmonella Typhi fragmented Vi-CRM conjugate were used. Both antigens rapidly and completely desorbed from alum after incubation with serum, verified via a competitive ELISA assay, and set up to rapidly evaluate in vitro antigen desorption from alum. After antigen modification with phosphoserines, desorption from alum was slowed down, and modified antigens demonstrated more prolonged retention at the injection sites through in vivo optical imaging in mice. Both modified antigens elicited stronger immune responses in mice, after a single injection only, compared to unmodified antigens. A stronger binding to alum could result in potent single-dose vaccine candidates and opens the possibility to design novel carrier proteins for glycoconjugates and improved versions of bacterial recombinant proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.
- GSK, Stevenage SG1 2NFX, Hertfordshire, UK.
ORCID-Profile: Francesca Mancini, Omar Rossi, Carlo Giannelli
Förderung
- GlaxoSmithKline Biologicals SA
Zitieren
APA
Di Benedetto, R., Massai, L., Wright, M., Mancini, F., Cleveland, M., Rossi, O., Giannelli, C., Berlanda Scorza, F., & Micoli, F. (2024). Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines. International Journal of Molecular Sciences, 25(21), 11461. https://doi.org/10.3390/ijms252111461
Vancouver
Di Benedetto R, Massai L, Wright M, Mancini F, Cleveland M, Rossi O, et al. Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines. International Journal of Molecular Sciences. 2024;25(21):11461. doi:10.3390/ijms252111461
BibTeX
@article{DiBenedetto2024,
author = {Di Benedetto, Roberta and Massai, Luisa and Wright, Mark and Mancini, Francesca and Cleveland, Matthew and Rossi, Omar and Giannelli, Carlo and Berlanda Scorza, Francesco and Micoli, Francesca},
title = {Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {21},
pages = {11461},
doi = {10.3390/ijms252111461}
}
EUVIMED